Upadacitinib 诱导活动性溃疡性结肠炎缓解的随机试验疗效
这项多中心双盲 2b 期研究纳入 250 例中重度活动性 UC 且对激素、免疫抑制剂和/或生物制剂应答不足、失应答或不耐受的成人,随机接受安慰剂或 upadacitinib(7.5、15、30、45 mg 缓释)每日一次共 8 周。第 8 周临床缓解率在 7.5、15、30、45 mg 组分别为 8.5%、14.3%、13.5%、19.6%,安慰剂组为 0;内镜改善率同样高于安慰剂。
要点
- 8 周 upadacitinib 诱导临床缓解率随剂量升高,45 mg 组达 19.6%,安慰剂组为 0。
- 内镜改善率 7.5、15、30、45 mg 组分别为 14.9%、30.6%、26.9%、35.7%,安慰剂组 2.2%。
- 45 mg 组报告 1 例带状疱疹及 1 例肺栓塞合并深静脉血栓。
核心结论
- 在中重度活动性 UC 患者中,8 周 upadacitinib 诱导缓解疗效优于安慰剂。
研究设计与样本
- 多中心、双盲、2b 期研究,纳入 250 例中重度活动性 UC 且对激素、免疫抑制剂和/或生物制剂应答不足、失应答或不耐受的成人。
- 患者随机接受安慰剂或 upadacitinib 7.5、15、30、45 mg 缓释剂每日一次,共 8 周。
主要发现
- 第 8 周临床缓解率:7.5 mg 组 8.5%(P = .052)、15 mg 组 14.3%(P = .013)、30 mg 组 13.5%(P = .011)、45 mg 组 19.6%(P = .002),安慰剂组为 0。
- 第 8 周内镜改善(内镜子评分 ≤ 1)率:7.5 mg 组 14.9%(P = .033)、15 mg 组 30.6%(P < .001)、30 mg 组 26.9%(P < .001)、45 mg 组 35.7%(P < .001),安慰剂组 2.2%。
- 45 mg 组报告 1 例带状疱疹,以及 1 例肺栓塞合并深静脉血栓(于停药后 26 天诊断)。
- 观察到 upadacitinib 组血清脂质水平和肌酸磷酸激酶升高。
临床怎么用
- 对于中重度活动性 UC 且对常规治疗或生物制剂应答不足的患者,可考虑 upadacitinib 8 周诱导治疗。
- 使用 upadacitinib 期间需关注带状疱疹、血栓事件及血脂和肌酸磷酸激酶升高。
局限性
- 本研究为 2b 期诱导试验,未进行多重性校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We evaluated the efficacy and safety of upadacitinib, an oral selective inhibitor of Janus kinase 1, as induction therapy for ulcerative colitis (UC). METHODS: We performed a multicenter, double-blind, phase 2b study of 250 adults with moderately to severely active UC and an inadequate response, loss of response, or intolerance to corticosteroids, immunosuppressive agents, and/or biologic therapies. Patients were randomly assigned to groups that received placebo or induction therapy with upadacitinib (7.5 mg, 15 mg, 30 mg, or 45 mg, extended release), once daily for 8 weeks. The primary endpoint was the proportion of participants who achieve clinical remission according to the adapted Mayo score at week 8. No multiplicity adjustments were applied. RESULTS: At week 8, 8.5%, 14.3%, 13.5%, and 19.6% of patients receiving 7.5 mg, 15 mg, 30 mg, or 45 mg upadacitinib, respectively, achieved clinical remission compared with none of the patients receiving placebo (P = .052, P = .013, P = .011, and P = .002 compared with placebo, respectively). Endoscopic improvement at week 8, defined as endoscopic subscore of ≤ 1, was achieved in 14.9%, 30.6%, 26.9%, and 35.7% of patients receiving upadacitinib 7.5 mg, 15 mg, 30 mg, or 45 mg, respectively, compared with 2.2% receiving placebo (P = .033, P < .001, P < .001, and P < .001 compared with placebo, respectively). One event of herpes zoster and 1 participant with pulmonary embolism and deep venous thrombosis (diagnosed 26 days after treatment discontinuation) were reported in the group that received upadacitinib 45 mg once daily. Increases in serum lipid levels and creatine phosphokinase with upadacitinib were observed. CONCLUSION: In a phase 2b trial, 8 weeks of treatment with upadacitinib was more effective than placebo for inducing remission in patients with moderately to severely active UC. (ClinicalTrials.gov, Number: NCT02819635).
引用
- Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020. PMID: 32092309. doi:10.1053/j.gastro.2020.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。